Peripheral T-Cell Lymphoma (PTCL) Market

In 2017, the total incident population of Peripheral T-Cell Lymphoma (PTCL) in 7MM was 16,298.

The market size of Peripheral T-Cell Lymphoma (PTCL) in 7MM was found to be USD 815.38 Million in 2017, which is expected to increase during the forecast period 2017-2030.

The key players in the Peripheral T-Cell Lymphoma (PTCL) market includes Eisai, Verastem Oncology, Affimed, Aileron Therapeutics, Solasia Pharma, Genor Biopharma, Bristol-Myers Squibb, AB Science, CerRx Inc., Celgene, Pfizer, Novartis/Incyte, Kura Oncology, BeiGene, Merck, PharmaMar, HUYA Bioscience International, Innate Pharma, Sorrento Therapeutics, Astex Pharmaceuticals, Otsuka Pharmaceutical and others.

For more detailed information on Peripheral T-Cell Lymphoma (PTCL) Market, visit:
https://www.delveinsight.com/report-store/peripheral-t-cell-lymphoma-ptcl-market